Avastin pockets another Priority Review label

Share this article:

Roche subsidiary Genentech has landed its second Priority Review label in two weeks for cancer drug Avastin. This week's status was tagged to a proposed indication for patients with recurring platinum-resistant ovarian cancer, paired with chemotherapy. Last week's Priority Review status was for patients with persistent, recurrent or metastatic cervical cancer, and was also paired with chemotherapy.

Chief medical officer and head of global product development Sandra Horning said in a statement that an approved ovarian cancer indication could be critical because “the majority of women with ovarian cancer will become resistant to platinum therapy and a quarter of women will have platinum-resistant disease at the time of first recurrence.”

The FDA is expected to vote yea or nay on the indication by November 19.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.